Drugs / ALVAC-CMV (vCP260)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00353977 | May 2004 → Mar 2008 | cytomegalovirus infection | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC-CMV (vCP260) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00353977 ↗ |
| Known as | ALVAC-pp65 (vCP260) | “ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.” NCT00353977 ↗ |
| Modality | Vaccine | “ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine” NCT00353977 ↗ |
| Route | Intramuscular | “delivered intramuscularly in the deltoid muscle” NCT00353977 ↗ |